- Raw materials
- Barbiturates
- Bromisoval
Bromisoval API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Bromisoval | CAS No: 496-67-3 | GMP-certified suppliers
A medication that acts as a central nervous system depressant and sedative, primarily used for investigational applications in managing sleep and anxiety disorders.
Therapeutic categories
Product Snapshot
- Bromisoval is an oral small molecule formulation
- It is primarily investigated for central nervous system indications such as sedation and anxiolysis
- The compound currently holds experimental status and lacks approval from major regulatory agencies including FDA and EMA
Clinical Overview
The compound is considered experimental and has not been widely approved for clinical use, limiting available information on its mechanism of action. Given its grouping with CNS depressants and hypnotics, bromisoval is presumed to exert CNS depressant activity, potentially through modulation of neuronal excitability or synaptic transmission, as is typical for compounds within this class.
Key pharmacokinetic parameters—including absorption, distribution, metabolism, and excretion (ADME)—have not been comprehensively described. Consequently, no definitive data are available on its bioavailability, metabolic pathways, half-life, or clearance mechanisms.
Safety and toxicity profiles of bromisoval have not been thoroughly evaluated. As with many CNS depressants, potential risks may include central nervous system depression, respiratory depression, and dependency, but specific toxicological data are lacking. No globally recognized pharmaceutical brands currently market bromisoval, reflecting its experimental status and limited clinical adoption.
From an API sourcing and quality perspective, procurement of bromisoval necessitates adherence to rigorous quality standards to ensure chemical purity and consistency. Given the absence of widespread clinical use and regulatory approval, suppliers must provide comprehensive documentation regarding synthesis, impurity profiles, and stability. Compliance with applicable pharmacopoeial standards and regulatory guidelines is essential to support any investigational use or research application.
Identification & chemistry
| Generic name | Bromisoval |
|---|---|
| Molecule type | Small molecule |
| CAS | 496-67-3 |
| UNII | 469GW8R486 |
| DrugBank ID | DB13370 |
Formulation & handling
- Bromisoval is a small molecule suitable for oral formulation due to its moderate water solubility and low logP.
- The compound's stability profile suggests standard handling protocols without special storage conditions.
- Its classification as a carboximidic acid derivative indicates potential sensitivity to hydrolytic conditions during formulation.
Regulatory status
Bromisoval is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
